Breaking News Instant updates and real-time market news.

DRNA

Dicerna

$14.89

-0.35 (-2.30%)

, DERM

Dermira

$11.50

-0.17 (-1.46%)

04:55
10/03/18
10/03
04:55
10/03/18
04:55

Cantor Fitzgerald to hold a conference

Global Healthcare Conference will be held in New York on October 1-3.

DRNA

Dicerna

$14.89

-0.35 (-2.30%)

DERM

Dermira

$11.50

-0.17 (-1.46%)

AUPH

Aurinia Pharmaceuticals

$6.44

0.16 (2.55%)

ONCS

OncoSec

$1.44

0.05 (3.60%)

QURE

uniQure

$33.51

-0.4 (-1.18%)

ADRO

Aduro Biotech

$6.25

-0.935 (-13.02%)

TGTX

TG Therapeutics

$5.49

-0.02 (-0.36%)

PACB

Pacific Biosciences

$4.81

-0.345 (-6.70%)

NEO

NeoGenomics

$14.57

-0.45 (-3.00%)

NBRV

Nabriva Therapeutics

$2.73

-0.02 (-0.73%)

CPSI

Computer Programs

$26.47

-0.04 (-0.15%)

BLCM

Bellicum Pharmaceuticals

$6.17

0.06 (0.98%)

LNTH

Lantheus

$14.91

0.01 (0.07%)

PLI

Proliance International

$0.00

(0.00%)

SELB

Selecta Biosciences

$15.50

-0.4397 (-2.76%)

TTOO

T2 Biosystems

$6.82

0.1 (1.49%)

OMED

OncoMed

$2.14

0.08 (3.88%)

CERS

Cerus

$7.10

-0.05 (-0.70%)

DRRX

Durect

$1.06

-0.02 (-1.86%)

INSM

Insmed

$15.99

0.29 (1.85%)

OCUL

Ocular Therapeutix

$6.79

-0.32 (-4.50%)

  • 03

    Oct

  • 03

    Oct

  • 03

    Oct

  • 03

    Oct

  • 04

    Oct

  • 09

    Oct

  • 11

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 08

    Nov

  • 27

    Nov

  • 28

    Dec

DRNA Dicerna
$14.89

-0.35 (-2.30%)

09/17/18
RILY
09/17/18
NO CHANGE
Target $10
RILY
Neutral
Dicerna shares are 'priced for perfection,' says B. Riley FBR
B. Riley FBR analyst Madhu Kumar lowered his price target for Dicerna Pharmaceuticals to $10 from $13.50 following the company's secondary offering. The shares are "priced for perfection" ahead of Phyox full data for DCR-PHXC in Q4, Kumar tells investors in a research note. He keeps a Neutral rating on the shares.
09/13/18
09/13/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Weight Watchers (WTW) initiated with an Equal Weight at Morgan Stanley. 2. AMSC (AMSC) initiated with a Buy at Craig-Hallum. 3. AudioEye (AEYE) initiated with a Buy at B. Riley FBR. 4. Lamar Advertising (LAMR) initiated with an Outperform at Imperial Capital. 5. Dicerna (DRNA) initiated with a Buy at Citi. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/13/18
SBSH
09/13/18
INITIATION
Target $27
SBSH
Buy
Citi starts Dicerna with Buy rating, $27 price target
Citi analyst Robyn Karnauskas initiated coverage of Dicerna Pharmaceuticals with a Buy rating and $27 price target. The analyst sees upside potential of up to three times the current price, and downside risk to the company's cash levels, on success in primary hyperoxaluria. The analyst calls her risk/reward conservative because she assigns 50% probability to primary hyperoxaluria Type 1 and 2. At 100% probability his price target would be $58. Hepatitis B virus is upside to her current model, Karnauskas points out.
09/13/18
SBSH
09/13/18
INITIATION
Target $27
SBSH
Buy
Dicerna initiated with a Buy at Citi
Citi analyst Robyn Karnauskas started Dicerna Pharmaceuticals with a Buy rating and $27 price target.
DERM Dermira
$11.50

-0.17 (-1.46%)

03/06/18
GUGG
03/06/18
DOWNGRADE
GUGG
Neutral
Dermira downgraded to Neutral from Buy at Guggenheim
03/06/18
NEED
03/06/18
NO CHANGE
Target $19
NEED
Buy
Dermira price target lowered to $19 from $43 at Needham
Needham analyst Serge Belanger lowered his price target on Dermira to $19 from $43 after the company's failed DRM01 acne program due to "surprising and disappointing failures across the phase 3 CLAREOS trials". Belanger states that the focus now shifts to Dermira's other assets such as hyperhidrosis which has a PDUFA at the end of June and lebrikizumab which is currently in a phase 2 study with expected readout in mid-2019. The analyst keeps his Buy rating, noting that the sell-off following the DRM01 announcement does not take into account Dermira's remaining asset values.
05/25/18
CANT
05/25/18
NO CHANGE
Target $20
CANT
Overweight
Dermira 23% selloff not based on fundamentals, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen says she sees no fundamental reason for the 23% decline yesterday in shares of Dermira. The analyst day underscored the opportunities for glycopyrronium tosylate in excessive sweating and Lebrikizumab in atopic dermatitis, Chen tells investors in a research note. She believes glycopyrronium tosylate approval should drive the stock higher and keeps an Overweight rating on the name with a $20 price target. Chen notes that investors she spoke with were concerned that consensus numbers need to come down.
05/25/18
NEED
05/25/18
NO CHANGE
Target $16
NEED
Buy
Dermira price target lowered to $16 from $19 at Needham
Needham analyst Serge Belanger lowered his price target on Dermira to $16 after the company's inaugural analyst day which focused on the commercial launch strategy for DRM04 to reflect the higher than anticipated launch costs for the program. The analyst keeps his Buy rating however, saying his expectations for FDA approval of DRM04 are high given the "solid" phase 3 data, forecasting the treatment to have a significant role in the hyperhidrosis market which currently has few effective alternatives. Belanger adds that the stock price "undervalues DRM04's potential and largely ignores the lebrikizumab program".
AUPH Aurinia Pharmaceuticals
$6.44

0.16 (2.55%)

10/30/17
HCWC
10/30/17
NO CHANGE
Target $12
HCWC
Buy
Aurinia Pharmaceuticals price target raised to $12 from $10 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Aurinia Pharmaceuticals to $12 after the company at its recent analyst day announced plans to expand voclosporin development to include focal segmental glomerulosclerosis and minimal change disease. The analyst maintains a Buy rating on the shares.
02/08/18
RBCM
02/08/18
INITIATION
Target $9
RBCM
Outperform
Aurinia Pharmaceuticals initiated with an Outperform at RBC Capital
RBC Capital analyst Douglas Miehm initiated Aurinia Pharmaceuticals with an Outperform rating and a price target of $9. The analyst says the stock represents an "attractive opportunity with upside" based on the Phase 3 study of its lupus nephritis drug voclosporin, which "has potential to become the first FDA-approved treatment for the disease".
03/16/18
CANT
03/16/18
NO CHANGE
Target $16
CANT
Overweight
Aurinia price target raised to $16 from $14 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros raised his price target for Aurinia Pharmaceuticals to $16 citing a reduction of the company's estimated tax rate to 21% from 35% following its Q4 results. Aurinia remains on track to enroll its Phase 3 Aurora study in Q4 and to initiate studies to advance its pipeline indications for voclosporin in Q2, Piros tells investors in a research note. He reiterates an Overweight rating on the shares.
08/13/18
HCWC
08/13/18
NO CHANGE
Target $15
HCWC
Buy
Aurinia Pharmaceuticals price target raised to $15 from $12 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Aurinia Pharmaceuticals to $15 after the company announced its pivotal Phase 3 study of voclosporin in lupus nephritis patients is running ahead of schedule. The analyst view the progress as a reflection of the high level of interest and motivation in the trial, by both patients and investigators. He keeps a Buy rating on Aurinia shares.
ONCS OncoSec
$1.44

0.05 (3.60%)

08/14/18
PIPR
08/14/18
NO CHANGE
Target $5
PIPR
Overweight
OncoSec price target raised to $5 from $4 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for OncoSec Medical to $5 saying tavokinogene telseplasmid has demonstrated proof-of-concept data in relapsed/refractory melanoma. The analyst expects final Phase II OMS-100 monotherapy plus preliminary Phase IIb data at the Society for Immunotherapy of Cancer meeting in November. Depending upon the strength of data in Stage 2 of this trial, OncoSec may be able to seek accelerated approval in melanoma in 2020, Tenthoff tells investors in a research note after taking over coverage of the name. He maintains Piper's Overweight rating on OncoSec.
02/09/18
PIPR
02/09/18
INITIATION
Target $4
PIPR
Overweight
OncoSec initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Charles Duncan started OncoSec Medical with an Overweight rating and $4 price target. The company's lead candidate ImmunoPulse in checkpoint inhibitor refractory metastatic melanoma "offers a differentiated approach," the analyst contends. He sees potential for $350M in peak U.S. revenues for IP IL-12 in this initial population following a 2020 launch.
10/19/17
MAXM
10/19/17
NO CHANGE
Target $5
MAXM
Buy
OncoSec data continues to build for Keytruda combination, says Maxim
Maxim analyst Jason McCarthy noted that OncoSec (ONCS) presented "positive" data demonstrating that at 6 months the combination of the company's TAVO with Merck's (MRK) Keytruda in melanoma patients that are non-responders to checkpoint therapy induced a best overall response rate of 50%. The Phase 2b registration study with Merck is now underway and good results would be a "significant incentive" for Merck to support the combination, said McCarthy, who keeps a Buy rating and $5 price target on OncoSec shares.
QURE uniQure
$33.51

-0.4 (-1.18%)

09/24/18
HCWC
09/24/18
NO CHANGE
Target $48
HCWC
Buy
uniQure price target raised to $48 from $42 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay raised his price target for uniQure to $48 with all the patients successfully dosed in the dose-confirmation study of AMT-061. With all patients now successfully dosed in the dose-confirmation study of AMT-061 and a previously disclosed six to eight weeks follow-up, the stage is now set for the company to unveil top-line data and confirm dosing for its Phase III HOPE-B pivotal study, which is on schedule by year end 2018, Chattopadhyay tells investors in a research note. He keeps a Buy rating on uniQure.
08/08/18
JANY
08/08/18
NO CHANGE
JANY
Buy
uniQure weakness a buying opportunity, says Janney Montgomery Scott
Janney Montgomery Scott analyst Yun Zhong said all of uniQure's programs are on track and that weakness in the shares after earnings is a buying opportunity. Zhong keeps a Buy rating on uniQure shares.
07/27/18
07/27/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. NXP Semiconductors (NXPI) reinstated with a Neutral at BofA/Merrill. 2. uniQure (QURE) initiated with an Overweight at Cantor Fitzgerald. 3. Autolus Therapeutics (AUTL) initiated with a Neutral at Goldman Sachs. 4. Pure Storage (PSTG) initiated with an Overweight at JPMorgan. 5. Plains All American (PAA) initiated with a Buy at Seaport Global. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/27/18
CANT
07/27/18
INITIATION
Target $58
CANT
Overweight
Cantor starts uniQure with Overweight rating, $58 price target
Cantor Fitzgerald analyst Elemer Piros last night initiated coverage of uniQure with an Overweight rating and $58 price target. Given the previous success in hemophilia gene therapy trials along with the FDA stance, uniQure has the potential to be the leader in hemophilia B treatment, Piros tells investors in a research note. To the analyst's knowledge, the most competitive indication to be addressed by gene therapy is hemophilia. He believes the FDA is noticing too.
ADRO Aduro Biotech
$6.25

-0.935 (-13.02%)

02/21/18
CANT
02/21/18
INITIATION
Target $15
CANT
Overweight
Aduro Biotech initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald started Aduro Biotech with an Overweight rating and $15 price target.
12/13/17
HCWC
12/13/17
NO CHANGE
Target $9.5
HCWC
Buy
Aduro Biotech price target lowered to $9.50 from $18 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis lowered his price target for Aduro Biotech to $9.50 after the company announced the termination of its three CRS-207 clinical studies and discontinuation of the program due to insufficient clinical activity. The analyst believes investors placed limited value to this program after the May 2016 failure of the Phase 2b study in pancreatic cancer. Aduro has a diverse set of candidates in the pipeline which it will place more focus on as a result of CRS-207 based programs being terminated, Pantginis tells investors in a research note. He keeps a Buy rating on Aduro.
02/22/18
02/22/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Loxo Oncology (LOXO) initiated with an Outperform at Oppenheimer. 2. Asterias (AST) initiated with a Buy at B. Riley FBR. 3. Viveve (VIVE) initiated with a Buy at Empire. 4. Panhandle Oil & Gas (PHX) initiated with a Buy at Roth Capital. 5. Aduro Biotech (ADRO) initiated with an Overweight at Cantor Fitzgerald. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/22/18
CANT
02/22/18
INITIATION
Target $15
CANT
Overweight
Cantor likes Aduro's immuno-oncology pipeline, starts at Overweight
Cantor Fitzgerald analyst Mara Goldstein last night initiated Aduro Biotech with an Overweight rating and $15 price target. The analyst likes the company's "broad pipeline," which she believes has the potential to translate into large market opportunities based on several novel immuno-oncology candidates. She expects upcoming catalysts and milestones to expand Aduro's valuation.
TGTX TG Therapeutics
$5.49

-0.02 (-0.36%)

09/26/18
HCWC
09/26/18
NO CHANGE
Target $21
HCWC
Buy
TG Therapeutics price target lowered to $21 from $38 at H.C. Wainwright
H.C. Wainwright analyst Edward White lowered his price target for TG Therapeutics to $21 after the company announced that the independent Data Safety Monitoring Board for the ongoing Phase 3 UNITY-CLL trial in chronic lymphocytic leukemia patients advised the company that interim overall response rate analysis could not be conducted at this time due to the data not being sufficiently mature to conduct the analysis. The analyst pushed back the timing of his expectations of the launch for chronic lymphocytic leukemia to early 2021 from late 2019 and lowered the probability of success to 45% in the CLL indication from 55%. He keeps a Buy rating on TG Therapeutics.
06/04/18
HCWC
06/04/18
NO CHANGE
Target $38
HCWC
Buy
TG Therapeutics ASCO update an incremental positive, says H.C. Wainwright
H.C. Wainwright analyst Edward White said he believes TG Therapeutics' poster presentation at ASCO further supports his view that umbralisib is a differentiated oral PI3K delta inhibitor. White, who notes that the Phase 3 UNITY-CLL trial remains on target for ORR data this summer, keeps a Buy rating and $38 price target on TG Therapeutics shares.
09/25/18
RAJA
09/25/18
DOWNGRADE
RAJA
Outperform
TG Therapeutics downgraded to Outperform from Strong Buy at Raymond James
09/26/18
RHCO
09/26/18
NO CHANGE
Target $30
RHCO
Buy
TG Therapeutics price target lowered to $30 from $35 at SunTrust
SunTrust analyst Peter Lawson lowered his price target on TG Therapeutics to $30 after the announcement that the independent Data Safety Monitoring Board for the ongoing Phase 3 UNITY-CLL trial in chronic lymphocytic leukemia, or CLL, patients advised that the data "was not mature enough" to read out the overall response rate. The analyst says the company has decided to not seek accelerated approval, which could delay market entry, focusing instead on the Progression-Free Survival endpoint to support approval. While Lawson remains bullish on the stock and maintains his Buy rating, he notes that his revised price target reflects the lower probability of success in the CLL program.
PACB Pacific Biosciences
$4.81

-0.345 (-6.70%)

08/08/18
CANT
08/08/18
INITIATION
Target $5
CANT
Overweight
Pacific Biosciences initiated with an Overweight at Cantor Fitzgerald
Cantor analyst Jordan Abrams initiated Pacific Biosciences with an Overweight and $5 price target.
08/09/18
CANT
08/09/18
INITIATION
Target $5
CANT
Overweight
Cantor starts Pacific Biosciences with Overweight rating, $5 target
Cantor Fitzgerald analyst Jordan Abrams last night initiated coverage of Pacific Biosciences of California with an Overweight rating and $5 price target. The analyst thinks Pacific's long-read next generation sequencing platform is the industry standard for deep genomic analysis in human, plant, and animal genomes, as well as RNA. While the company has seen mixed revenue performance over the past three years, it is "getting close to an inflection point," which the Street is missing, Abrams told investors in a research note. He sees "multiple paths to revenue acceleration."
07/18/18
PIPR
07/18/18
NO CHANGE
Target $3.25
PIPR
Neutral
Pacific Biosciences Q2 shaping up as good quarter, says Piper Jaffray
Piper Jaffray analyst William Quirk says his channel checks found 15 Sequels placed in Q2, suggesting Pacific Biosciences had a sequential increase in placements, consistent with management's comments on the Q1 call and slightly ahead of his expectations. The company's Q2 appears to be shaping up as a good quarter ahead of its 2019 introduction of the 8M feature chip, Quirk tells investors in a research note. The analyst is "encouraged" with Pacific's progress, but keeps a Neutral rating on the shares with a $3.25 price target citing the "complex competitive dynamics."
08/09/18
08/09/18
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Pacific Biosciences (PACB) initiated with an Overweight at Cantor Fitzgerald by analyst Jordan Abrams, who thinks Pacific's long-read next generation sequencing platform is the industry standard for deep genomic analysis in human, plant, and animal genomes, as well as RNA. 2. Heico (HEI) initiated with a Neutral at Baird. 3. Zynga (ZNGA) initiated with an Underweight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
NEO NeoGenomics
$14.57

-0.45 (-3.00%)

08/21/18
LEER
08/21/18
INITIATION
Target $18
LEER
Outperform
NeoGenomics initiated with an Outperform at Leerink
Leerink analyst Puneet Souda started NeoGenomics with an Outperform rating and $18 price target. The analyst believes the company is a "uniquely" positioned one-stop shop oncology testing service provider with faster turnaround times versus its competition and a tech-only model that has helped it grow to the current levels. Souda projects NeoGenomics to deliver a 13% sales CAGR and about 25% adjusted EBITDA growth over the longer-term.
05/02/18
FANA
05/02/18
DOWNGRADE
Target $11
FANA
Equal-Weight
NeoGenomics downgraded to Equal-Weight from Overweight at First Analysis
First Analysis analyst Joseph Munda downgraded NeoGenomics to Equal-Weight citing valuation following the company's Q1 results. The analyst says NeoGenomics' fundamentals remain attractive. He has an $11 price target for the shares.
04/16/18
BTIG
04/16/18
UPGRADE
Target $11
BTIG
Buy
NeoGenomics upgraded to Buy at BTIG on solid volume trends and cost cuts
As reported earlier, BTIG analyst Sean Lavin upgraded NeoGenomics to Buy from Hold with a price target of $11. Lavin says the issues around exposure to Texas and Florida markets as well as lingering issues around Clarient have "largely dissipated". While the analyst remains concerned about the risk of "unexpected reimbursement changes", he adds that Medicare pricing for 2018 being in place cushions the risk around NeoGenomics guidance, while its growing Biopharma business and cost-cutting provide higher growth potential for the stock over time.
09/18/18
FANA
09/18/18
NO CHANGE
Target $16
FANA
Outperform
NeoGenomics price target raised to $16 from $14 at First Analysis
First Analysis analyst Joseph Munda raised his price target for NeoGenomics to $16 following meetings with management. The analyst now has reinforced confidence that the company's "one-stop oncology testing shop" remains well positioned to scale its pharma services business and to continue to take clinical testing market share. He keeps an Outperform rating on NeoGenomics.
NBRV Nabriva Therapeutics
$2.73

-0.02 (-0.73%)

05/31/18
CANT
05/31/18
NO CHANGE
Target $16
CANT
Overweight
Nabriva Therapeutics valuation 'hard to resist,' says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen says she left meetings with Nabriva Therapeutics management even more convinced that the market opportunity for lefamulin is underappreciated. Nabriva Therapeutics shares have been weak since the company announced positive data from its second Phase 3 study, Chen tells investors in a research note titled "NBRV Hard to Resist At Its Current Valuation." She sees no fundamental reason for the weakness and keeps an Overweight rating on the shares with a $16 price target.
05/31/18
NORL
05/31/18
INITIATION
Target $17.5
NORL
Outperform
Nabriva Therapeutics initiated with an Outperform at Northland
Northland initiated Nabriva Therapeutics with an Outperform and $17.50 price target.
08/27/18
BOFA
08/27/18
NO CHANGE
Target $5
BOFA
Buy
Nabriva Therapeutics price target lowered to $5 from $9 at BofA/Merrill
BofA/Merrill analyst Jason Gerberry lowered his price target on Nabriva Therapeutics to $5, citing his lower expected probability of success of 60% vs. 75% prior in its recently acquired CONTEPO for complicated urinary tract infection. The analyst says the program's main risk is an "imbalance of liver enzyme elevation while a slightly higher dose reduces read -through from about a 45-year post-market EU safety". Gerberry now believes that CONTEPO is a "niche opportunity", and lowers his peak sales view to $50M from $80M prior. The analyst also keeps his Buy rating on Nabriva on valuation as well as the opportunity for its two FDA action dates for lefamulin and CONTEPO in the second half of 2019.
09/07/18
MSCO
09/07/18
INITIATION
Target $8
MSCO
Overweight
Nabriva Therapeutics resumed with an Overweight at Morgan Stanley
Morgan Stanley analyst David Lebowitz resumed coverage of Nabriva Therapeutics with an Overweight rating and a $8 price target, stating that its "first-in-class" antibiotics lefamulin and Contepo both have approvable Phase 3 data. He believes at current levels Nabriva shares are pricing in a "worst case scenario" for both antibiotics, but he sees it as likely that Nabriva exceeds the low expectations. Lebowitz forecasts risk-adjusted 2025 sales for lefamulin and Contepo of $228M and $33M, respectively.
CPSI Computer Programs
$26.47

-0.04 (-0.15%)

01/04/18
SBSH
01/04/18
INITIATION
Target $33
SBSH
Neutral
Computer Programs initiated with a Neutral at Citi
Citi analyst Stephanie Davis started Computer Programs and Systems with a Neutral rating and $33 price target. The analyst believes greater competition in the community hospital market could create headline risk in the near term.
08/03/18
PIPR
08/03/18
NO CHANGE
Target $29
PIPR
Neutral
Computer Programs price target lowered to $29 from $32 at Piper Jaffray
Piper Jaffray analyst Sean Wieland lowered his price target on Computer Programs to $29 after its Q2 earnings miss, saying the wide margin was attributed mainly to client delays in purchasing Meaningful Use required systems. The analyst notes that the management is confident in the second half recovery given the queue of pending implementations, but still sees risks of "very high stimulus incentive eligibility requirements, less than anticipated EHR adoption despite stimulus incentives, and competition". Wieland keeps his Neutral rating on Computer Programs.
BLCM Bellicum Pharmaceuticals
$6.17

0.06 (0.98%)

04/12/18
CANT
04/12/18
NO CHANGE
Target $18
CANT
Overweight
Bellicum price target raised to $18 from $10 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros raised his price target for Bellicum Pharmaceuticals to $18 following the announcement of the FDA's lift of its U.S. clinical hold for BPX-501. The analyst now has increased confidence across the BPX-501 platform. He reiterates an Overweight rating on the shares.
04/11/18
WELS
04/11/18
UPGRADE
WELS
Outperform
Bellicum Pharmaceuticals upgraded to Outperform at Wells Fargo
03/14/18
JEFF
03/14/18
NO CHANGE
Target $16
JEFF
Buy
Bellicum clinical hold should lift soon, says Jefferies
Jefferies analyst Biren Amin says Bellicum Pharmaceuticals last night provided an update of its leading prgm BPX-501 with an "encouraging" survival rate at one year in pediatric acute myeloid leukemia patients. For BPX-601, management reported CART cell expansion in one pancreatic cancer patient following rimiducid administration, providing first patient validation of the company's activation switch, Amin tells investors in a post-earnings research note. The analyst notes Bellicum has also responded to FDA including proposed protocol changes. Amin believes the clinical hold should lift soon and keeps a Buy rating on Bellicum Pharmaceuticals with a $16 price target.
04/12/18
WELS
04/12/18
UPGRADE
Target $23
WELS
Outperform
Wells Fargo upgrades Bellicum to Outperform on lifting of clinical hold
Wells Fargo analyst Jim Birchenough last night upgraded Bellicum Pharmaceuticals to Outperform from Market Perform and raised his price target for the shares to $23 from $6. The shares in premarket trading are up 27% to $8.70 following news that the FDA lifted the clinical hold on studies of BPX-501 in the U.S. Rapid resolution of the clinical hold "substantially de-risks the investment," Birchenough tells investors in a research note. He believes Bellicum's platform for controllable cell therapies is well positioned for therapeutic oncology indications.
LNTH Lantheus
$14.91

0.01 (0.07%)

08/02/18
WELS
08/02/18
NO CHANGE
Target $20
WELS
Outperform
Lantheus price target lowered to $20 from $26 at Wells Fargo
Wells Fargo analyst Lawrence Biegelsen lowered his price target for Lantheus to $20 from $26 after the company reported Q2 revenue that missed Street expectations due to a TechneLite supply shortage but modestly beat consensus on adjusted EBITDA. The analyst reiterates an Outperform rating on the shares.
06/18/18
JEFF
06/18/18
NO CHANGE
Target $21
JEFF
Buy
Lantheus position in moly more secure than stock suggests, says Jefferies
A presentation by new molybdenum-99 supplier SHINE Medical Technologies adds more support to Lantheus' (LNTH) position in the market being more secure than the current stock price reflects, Jefferies analyst Raj Denhoy tells investors in a research note. SHINE expects to bring production online in 2021, with Lantheus already contracted to use its molybdenum-99, the analyst adds. He believes the market is "vastly overestimating" the threat from new entrants and "vastly underappreciating" the company's "hold on this market." Denhoy sees little chance of BWX Technologies (BWXT) gaining significant traction given the manufacturing and regulatory challenges in bringing a generator to market. He keeps a Buy rating on Lantheus with a $21 price target.
11/02/17
WELS
11/02/17
UPGRADE
Target $26
WELS
Outperform
Lantheus upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Larry Biegelsen upgraded Lantheus to Outperform saying the reimbursement overhang has been removed with the final hospital Outpatient Prospective Payment Rule rule maintaining the payment rate for echos with contrast and is largely unchanged year-over-year. Removing the risk of payment reduction clears the way for Lantheus to continue to deliver solid sales growth and improving EBITDA margin, the analyst tells investors in a research note. He raised his price target for the shares to $26 from $20.
PLI Proliance International
$0.00

(0.00%)

SELB Selecta Biosciences
$15.50

-0.4397 (-2.76%)

04/11/18
MZHO
04/11/18
NO CHANGE
Target $18
MZHO
Buy
Selecta drug not imminent threat to Horizon Pharma, says Mizuho
Mizuho analyst Irina Koffler says competitor Selecta Biosciences (SELB) released "directionally positive," but early, data on a potential competitive product to Horizon Pharma's key orphan drug Krystexxa. The analyst does not view Selecta's SEL-212 as an imminent threat to Horizon. She reiterates a Buy rating on Horizon with an $18 price target.
05/23/18
ADAM
05/23/18
NO CHANGE
Target $40
ADAM
Buy
Selecta Biosciences price target raised to $40 from $30 at Canaccord
Canaccord analyst John Newman raised his price target on Selecta Biosciences to $40 from $30 citing his revised estimates for the pricing of SEL-212. After raising his expectation to about $100,000 per patient annually, Newman increased his U.S. peak sales estimate for SEL-212 to $898M from $233M. He maintains a Buy rating on Selecta shares.
06/27/18
JANY
06/27/18
INITIATION
Target $33
JANY
Buy
Selecta Biosciences initiated with a Buy at Janney Montgomery Scott
Janney Montgomery Scott analyst Yun Zhong initiated Selecta Biosciences with a Buy rating and $33 fair value estimate.
09/13/18
STFL
09/13/18
INITIATION
STFL
Buy
Selecta Biosciences resumed with a Buy at Stifel
Stifel analyst Derek Archila resumed coverage of Selecta Biosciences with a Buy rating and $24 price target, saying he believes SEL-212's clinical data suggests an improved efficacy/tolerability profile and less frequent dosing than the current standard of care for severe chronic gout.
TTOO T2 Biosystems
$6.82

0.1 (1.49%)

06/01/18
06/01/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. American Airlines (AAL) upgraded to Outperform from In-Line at Imperial Capital with analyst Michael Derchin saying American is likely to reduce capacity starting in the post-labor day period, which should be well received by investors. 2. T2 Biosystems (TTOO) upgraded to Outperform from Market Perform at Leerink with analyst Puneet Souda saying this week's T2bacteria FDA clearance expands the company's market opportunity "dramatically" from $1.4B to over $3B. 3. Highwoods Properties (HIW) upgraded to Buy from Hold at Stifel with analyst John Guinee saying he believes the macro environment is changing to the positive for REITs. 4. Toyota (TM) upgraded to Outperform from Neutral at Daiwa. 5. RLJ Lodging Trust (RLJ) upgraded to Overweight from Equal Weight at Barclays with analyst Felicia Hendrix saying she views the current valuation as attractive and sees a strong RevPAR outlook for 2019. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/20/18
CANT
09/20/18
INITIATION
Target $11
CANT
Overweight
T2 Biosystems initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Jordan Abrams started T2 Biosystems with an Overweight rating and $11 price target. The analyst believes the company's direct-from-whole-blood species-specific technology has the potential to change the standard of care for sepsis diagnostics.
06/01/18
LEER
06/01/18
UPGRADE
LEER
Outperform
T2 Biosystems upgraded to Outperform from Market Perform at Leerink
06/01/18
LEER
06/01/18
UPGRADE
Target $12
LEER
Outperform
T2 Biosystems upgraded to Outperform with $12 target at Leerink
Leerink analyst Puneet Souda upgraded T2 Biosystems to Outperform from Market Perform and raised his price target for the shares to $12 from $5. This week's T2bacteria FDA clearance expands the company's market opportunity "dramatically" from $1.4B to over $3B, Souda tells investors in a research note. He believes T2 is "highly underpenetrated" in its core markets, but feels it can now penetrate the broader $1.5B-$2.0B bacterial sepsis market with an immediate entry into the hospital emergency departments, which the analyst values at $300M
OMED OncoMed
$2.14

0.08 (3.88%)

09/20/18
HCWC
09/20/18
NO CHANGE
Target $2
HCWC
Neutral
OncoMed price target lowered to $2 after Celgene pass at H.C. Wainwright
H.C. Wainwright analyst Edward White lowered his price target on OncoMed (OMED) shares to $2 from $3 after partner Celgene (CELG) passed on its option to license navicixizumab. Worldwide development, commercialization and rights to navicixizumab now remain under OncoMed's control while Celgene retains options to license OncoMed's anti-TIGIT monoclonal antibody, etigilimab, and anti-RSPO3, rosmantuzumab, noted White. The analyst, who notes there is potential the company could partner the asset, keeps a Neutral rating on OncoMed shares.
CERS Cerus
$7.10

-0.05 (-0.70%)

07/20/18
CANT
07/20/18
NO CHANGE
Target $9
CANT
Overweight
Cerus price target raised to $9 from $7 at Cantor Fitzgerald
Cantor Fitzgerald analyst Craig Bijou raised his price target for Cerus to $9 and reiterates an Overweight rating on the shares after hosting investor meetings with management. The analyst is now more confident that the company's recent momentum should continue. He believes Cerus has "various growth drivers for the next several years". The FDA is moving closer to providing final guidance for methods to reduce bacterial contamination in transfused platelets, and Cerus' pathogen-inactivation technology should be included, Bijou tells investors in a research note.
01/04/18
CANT
01/04/18
INITIATION
Target $5
CANT
Overweight
Cerus assumed with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald assumed coverage of Cerus with an Overweight rating and $5 price target.
DRRX Durect
$1.06

-0.02 (-1.86%)

10/20/17
STFL
10/20/17
DOWNGRADE
STFL
Hold
Durect downgraded to Hold from Buy at Stifel
10/20/17
HCWC
10/20/17
DOWNGRADE
HCWC
Neutral
Durect downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Ed Arce downgraded Durect to Neutral without a price target after the company said Posimir failed to meet its primary efficacy endpoint in the pivotal Phase 3 Persist study. He believes the partners will likely drop further development of Posimir and that Street sentiment on the shares will now be "show me".
10/20/17
10/20/17
DOWNGRADE
Target $0.9

Hold
Durect downgraded to Hold on 'major disappointment' of Posimir failure at Stifel
As previously reported, Stifel analyst Adam Walsh downgraded Durect (DRRX) to Hold from Buy, calling the fact that the company's Phase 3 Posimir trial in post-surgical pain did not meet its primary efficacy endpoint a "major disappointment." He has removed all Posimir revenue from his model and expects Novartis' (NVS) Sandoz will end the Posimir partnership. Walsh lowered his price target to 90c from $3.00 on Durect shares, which are down 55% to 87c in pre-market trading.
03/06/18
HCWC
03/06/18
UPGRADE
Target $3.5
HCWC
Buy
Durect upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright analyst Ed Arce upgraded Durect (DRRX) to Buy with a $3.50 price target. Investor sentiment has begun to shift to a positive bias, based on the broad preclinical and Phase 1 data set, and large commercial opportunity, of DUR-928, Acre tells investors in a research note. In addition to two Phase 2 data catalysts this year, investors can look to two near-term potential FDA approvals on partnered assets, Indivior's RBP-7000 and Pain Therapeutics' (PTIE) Remoxy, the analyst adds.
INSM Insmed
$15.99

0.29 (1.85%)

08/08/18
08/08/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. REACTIONS TO TESLA'S TALK OF GOING PRIVATE: Jefferies analyst Philippe Houchois raised his price target for Tesla (TSLA) to $360 from $250 after CEO Elon Musk suggested taking the company private. Going private "feels like the right thing to do," Houchois said. "Distraction or not, the move feels right even if Musk is downplaying how supportive public markets have been," the analyst adds. However, with Tesla unable to take on more debt, Houchois wondered who may fund the potential deal and end up as a new large shareholder. While Morgan Stanley analyst Adam Jonas sympathizes with Elon Musk's argument that Tesla could be better off as a private company, he questioned the feasibility of Musk actually being able to achieve that goal. Taking the company private would assume either that the company is on the verge of generating self-sustaining cash flows or that it can tap into a range of strategic sources of capital not previously at its disposal, said Jonas, who sees strategic value at Tesla but thinks the "LBO math required to support [a price of] $420 is extremely aggressive." MORGAN STANLEY SAYS SOUTHWEST A GOOD FIT FOR BERKSHIRE: Morgan Stanley analyst Kai Pan noted that Berkshire Hathaway (BRK.A) has shifted tone in recent years and become a top three shareholder of the "Big Four" U.S. airlines, including Southwest (LUV). Media reports from Forbes, CNN and others have discussed a possible acquisition by Berkshire of the airline, added Pan. He analyzed a theoretical acquisition and came to the conclusion that Southwest could be a strategic fit for Berkshire and the advantages could also be compelling for the airline. Pan estimates Berkshire could pay a 20-40% premium, or $70-80 per share for Southwest, in such a hypothetical takeover situation. Pan has an Overweight rating and $67 price target on Southwest shares. BARCLAYS POSITIVE ON SNAP GUIDANCE CHANGE: Barclays analyst Ross Sandler views Snap's (SNAP) Q2 results as a "mixed bag," with daily active users 2M below his estimate and revenue $20M above his estimate. More importantly, the change in approach towards guidance is "very welcomed and should help to reduce some of the volatility going forward," Sandler said. He believes this is a "big positive for long-term holders looking to get involved." The analyst kept an Overweight rating on Snap with a $16 price target. WAINWRIGHT SAYS INSMED LIKELY TO BE ACQUIRED: H.C. Wainwright analyst Andrew Fein raised his price target for Insmed (INSM) to $43 from $35 following the 12-2 FDA panel vote in favor of ALIS in refractory nontuberculous mycobacterial patients. Insmed is now likely to be acquired as ALIS "fits well within the pipeline of a number of larger companies," Fein said.
10/01/18
STFL
10/01/18
NO CHANGE
Target $43
STFL
Buy
Refractory label for Insmed Arikayce expected, black box a surprise, says Stifel
Stifel analyst Adam Walsh notes that Insmed received on-time FDA approval of Arikayce for the refractory NTM MAC population. Highlights included an unexpected black box warning on the label, the analyst notes, adding that he expects no impact on uptake. Additionally, Walsh points out that and WAC pricing of $132K far exceeded his prior $90K estimate. Near-term, he thinks deserved share upside on de-risking approval news may be partially offset by the unanticipated black box and cautious management tone on early launch. Regardless, the analyst sees solid value in the shares at current levels based on the Arikayce refractory opportunity alone, independent of planned future label-expansion possibilities. Walsh reiterates a Buy rating and $43 price target on the stock.
10/01/18
FBCO
10/01/18
NO CHANGE
Target $35
FBCO
Outperform
Insmed price target raised to $35 from $33 at Credit Suisse
Credit Suisse analyst Martin Auster notes that Insmed received on-time FDA approval of Arikayce for the treatment of refractory NTM MAC, in line with the FDA AdCom recommendation. In a research note to investors, Auster says approval came with "a few surmountable caveats," including a black box warning on the label, the requirement for a controlled, post-approval clinical trial in front-line NTM MAC and the limitation of Arikayce to refractory patients with limited or no options. Auster, who maintains an Outperform rating and raises his price target to $35 from $33, expects shares to rebound to pre-briefing doc levels.
09/19/18
GSCO
09/19/18
NO CHANGE
Target $25
GSCO
Neutral
Insmed price target lowered to $25 from $32 at Goldman Sachs
Goldman Sachs analyst Dana Flanders lowered his price target on Insmed to $25 to reflect the 22% decline in its stock price since August amid the rising uncertainty around the "likelihood of the phase 3 surrogate endpoint of culture conversion to predict clinical benefit" in ALIS study. The analyst is also keeping a Neutral rating on the stock citing his measured ALIS launch expectations, but sees its risk-reward more favorable going into the September 28th PDUFA, anticipating an ultimate approval for ALIS in the refractory setting "based on high unmet need for new treatment options in this orphan indication".
OCUL Ocular Therapeutix
$6.79

-0.32 (-4.50%)

01/19/18
BTIG
01/19/18
UPGRADE
Target $9
BTIG
Buy
Ocular Therapeutix upgraded to Buy from Neutral at BTIG
As reported earlier, BTIG analyst Dane Leone upgraded Ocular Therapeutix to Buy from Neutral with a price target of $9. Leone cites the new management's reset of expectation for a resubmission of the Dextenza NDA for post-surgical cataract patients for the first half of this year, which sets a "reasonable 6-month review table" to have approval by year-end. The analyst models Dextenza generating about $16M in sales in 2019 and rising to $116M by 2022.
03/08/18
CANT
03/08/18
NO CHANGE
Target $22
CANT
Overweight
Cantor Fitzgerald says Ocular Therapeutix set up for 'momentous' 2018
Following Ocular Therapeutix's Q4 report and call, during which the company reiterated its guidance to resubmit its application for DEXTENZA in the first half of 2018 and said it continues to anticipate the readout of its Phase 3 OTX-TP study in glaucoma in the fourth quarter, Cantor Fitzgerald analyst Elemer Piros said he expects a "momentous" year for the company. He keeps an Overweight rating on Ocular and raised his price target on the stock to $22 from $21.
09/06/18
PIPR
09/06/18
INITIATION
Target $14
PIPR
Overweight
Ocular Therapeutix initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro initiated Ocular Therapeutix with an Overweight rating and $14 price target, stating that he is confident that the issues raised in Dextenza's CRLs have been addressed well enough to warrant an FDA approval before the end of 2018. He believes Dextenza U.S. sales in the post-surgical setting can rise to $250M by 2025.
01/19/18
BTIG
01/19/18
UPGRADE
BTIG
Buy
Ocular Therapeutix upgraded to Buy from Neutral at BTIG

TODAY'S FREE FLY STORIES

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, ALXN

Alexion

$125.96

-0.63 (-0.50%)

04:55
10/21/18
10/21
04:55
10/21/18
04:55
Conference/Events
The ACR and ARHP to hold annual meeting »

American College of…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

AMGN

Amgen

$201.75

-1.03 (-0.51%)

AUPH

Aurinia Pharmaceuticals

$5.56

-0.13 (-2.28%)

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

CELG

Celgene

$82.42

-0.52 (-0.63%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FLXN

Flexion

$18.96

0.33 (1.77%)

GILD

Gilead

$73.27

-0.9 (-1.21%)

GSK

GlaxoSmithKline

$40.87

1.25 (3.16%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

RARE

Ultragenyx

$63.33

-0.77 (-1.20%)

QDEL

Quidel

$64.68

-2.85 (-4.22%)

PFE

Pfizer

$44.50

0.48 (1.09%)

NVS

Novartis

$87.19

0.95 (1.10%)

MRK

Merck

$72.34

0.12 (0.17%)

MCK

McKesson

$132.36

-0.34 (-0.26%)

LLY

Eli Lilly

$111.91

-1.4 (-1.24%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

SELB

Selecta Biosciences

$13.80

-1.34 (-8.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 02

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 09

    Nov

  • 27

    Nov

  • 11

    Jan

  • 16

    Feb

  • 18

    Feb

  • 28

    Apr

  • 13

    May

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, DCPH

Deciphera

$22.22

-4.97 (-18.28%)

04:55
10/21/18
10/21
04:55
10/21/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO 2018 Congress to be…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

DCPH

Deciphera

$22.22

-4.97 (-18.28%)

TSRO

Tesaro

$41.81

-1.19 (-2.77%)

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

CRSP

Crispr Therapeutics

$36.02

-1.18 (-3.17%)

CLVS

Clovis

$26.41

-3.54 (-11.82%)

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

RHHBY

Roche

$0.00

(0.00%)

NCNA

NuCana

$18.90

1.9 (11.18%)

CRVS

Corvus Pharmaceuticals

$8.01

-0.1 (-1.23%)

NTGN

Neon Therapeutics

$8.88

0.56 (6.73%)

NKTR

Nektar

$48.23

-1.33 (-2.68%)

EXEL

Exelixis

$16.27

-0.25 (-1.51%)

AVEO

Aveo Pharmaceuticals

$2.50

-0.03 (-1.19%)

KURA

Kura Oncology

$14.38

-1.18 (-7.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 28

    Oct

  • 30

    Oct

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 07

    Nov

  • 10

    Nov

  • 26

    Nov

  • 27

    Nov

  • 24

    Dec

  • 14

    Jan

  • 28

    Apr

  • 13

    May

04:55
10/21/18
10/21
04:55
10/21/18
04:55
Conference/Events
Morgan Stanley China hardware analyst to hold analyst/industry conference call »

China Hardware Tech…

BIIB

Biogen

$319.85

-10.4 (-3.15%)

14:57
10/20/18
10/20
14:57
10/20/18
14:57
Conference/Events
Biogen to host conference call »

Chief Medical Officer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 25

    Oct

SELB

Selecta Biosciences

$13.80

-1.34 (-8.85%)

14:13
10/20/18
10/20
14:13
10/20/18
14:13
Conference/Events
Selecta Biosciences to host conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

TROV

Trovagene

$1.12

-0.03 (-2.61%)

14:11
10/20/18
10/20
14:11
10/20/18
14:11
Conference/Events
Trovagene to host conference call »

Management provides an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLS

Sellas Life Sciences

$1.56

-0.24 (-13.33%)

13:54
10/20/18
10/20
13:54
10/20/18
13:54
Conference/Events
Sellas Life Sciences to host conference call »

Management provides a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 07

    Nov

NVS

Novartis

$87.19

0.95 (1.10%)

13:50
10/20/18
10/20
13:50
10/20/18
13:50
Conference/Events
Novartis to host conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 07

    Nov

UA

Under Armour

$16.79

-0.365 (-2.13%)

, UAA

Under Armour

$18.20

-0.42 (-2.26%)

12:43
10/20/18
10/20
12:43
10/20/18
12:43
Periodicals
Under Armour stock could triple, Barron's says »

Under Armour has had a…

UA

Under Armour

$16.79

-0.365 (-2.13%)

UAA

Under Armour

$18.20

-0.42 (-2.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 30

    Oct

  • 27

    Nov

  • 03

    Mar

STZ

Constellation Brands

$222.98

-2.36 (-1.05%)

, CGC

Canopy Growth

$46.87

-1.99 (-4.07%)

12:37
10/20/18
10/20
12:37
10/20/18
12:37
Periodicals
Constellation Brands changing CEOs, not marijuana strategy, Barron's says »

Constellation Brands…

STZ

Constellation Brands

$222.98

-2.36 (-1.05%)

CGC

Canopy Growth

$46.87

-1.99 (-4.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 14

    Nov

CFG

Citizens Financial

$36.36

1.44 (4.12%)

, AAPL

Apple

$219.28

3.3 (1.53%)

12:33
10/20/18
10/20
12:33
10/20/18
12:33
Periodicals
Citizens Financial stock worth buying, Barron's says »

Citizens Financial (CFG)…

CFG

Citizens Financial

$36.36

1.44 (4.12%)

AAPL

Apple

$219.28

3.3 (1.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$153.95

-1 (-0.65%)

, AAPL

Apple

$219.28

3.3 (1.53%)

12:26
10/20/18
10/20
12:26
10/20/18
12:26
Periodicals
Netflix emerged as winner in new way to rank big tech stocks risk, Barron's says »

A year ago,…

FB

Facebook

$153.95

-1 (-0.65%)

AAPL

Apple

$219.28

3.3 (1.53%)

AMZN

Amazon.com

$1,763.91

-7.54 (-0.43%)

NFLX

Netflix

$332.69

-14.02 (-4.04%)

GOOG

Alphabet

$1,096.41

8.51 (0.78%)

GOOGL

Alphabet Class A

$1,104.66

7.43 (0.68%)

DIS

Disney

$118.81

2.55 (2.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 07

    Nov

  • 08

    Nov

  • 13

    Nov

  • 03

    Mar

BABA

Alibaba

$142.90

1.1 (0.78%)

, TCEHY

Tencent

$0.00

(0.00%)

12:17
10/20/18
10/20
12:17
10/20/18
12:17
Periodicals
Chinese internet giants down, not out, Barron's says »

Alibaba (BABA), Tencent…

BABA

Alibaba

$142.90

1.1 (0.78%)

TCEHY

Tencent

$0.00

(0.00%)

BIDU

Baidu

$191.93

0.1 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 02

    Nov

BLK

BlackRock

$401.61

1.74 (0.44%)

, IVZ

Invesco

$22.00

0.74 (3.48%)

12:13
10/20/18
10/20
12:13
10/20/18
12:13
Periodicals
Fund companies sued by own employees over pricey 401k plans, Barron's says »

BlackRock (BLK),…

BLK

BlackRock

$401.61

1.74 (0.44%)

IVZ

Invesco

$22.00

0.74 (3.48%)

TROW

T. Rowe Price

$100.13

0.31 (0.31%)

SCHW

Charles Schwab

$46.81

0.11 (0.24%)

MTB

M&T Bank

$162.72

2.09 (1.30%)

MS

Morgan Stanley

$46.43

0.4 (0.87%)

JPM

JPMorgan

$107.92

-0.21 (-0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 24

    Oct

  • 26

    Feb

JPM

JPMorgan

$107.92

-0.21 (-0.19%)

, BLK

BlackRock

$401.61

1.74 (0.44%)

12:04
10/20/18
10/20
12:04
10/20/18
12:04
Periodicals
Khashoggi case puts financial ties to Saudis under strain, Barron's says »

The suspected killing of…

JPM

JPMorgan

$107.92

-0.21 (-0.19%)

BLK

BlackRock

$401.61

1.74 (0.44%)

BX

Blackstone

$34.66

-0.61 (-1.73%)

AMC

AMC Entertainment

$19.81

0.18 (0.92%)

IMAX

Imax

$22.45

-0.11 (-0.49%)

SIX

Six Flags

$66.40

-1.16 (-1.72%)

WWE

WWE

$82.02

-1.49 (-1.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 13

    Nov

  • 14

    Nov

  • 26

    Feb

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, ALXN

Alexion

$125.96

-0.63 (-0.50%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
The ACR and ARHP to hold annual meeting »

American College of…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

AMGN

Amgen

$201.75

-1.03 (-0.51%)

AUPH

Aurinia Pharmaceuticals

$5.56

-0.13 (-2.28%)

BMY

Bristol-Myers

$54.31

-1.7 (-3.04%)

CELG

Celgene

$82.42

-0.52 (-0.63%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FLXN

Flexion

$18.96

0.33 (1.77%)

GILD

Gilead

$73.27

-0.9 (-1.21%)

GSK

GlaxoSmithKline

$40.87

1.25 (3.16%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

RARE

Ultragenyx

$63.33

-0.77 (-1.20%)

QDEL

Quidel

$64.68

-2.85 (-4.22%)

PFE

Pfizer

$44.50

0.48 (1.09%)

NVS

Novartis

$87.19

0.95 (1.10%)

MRK

Merck

$72.34

0.12 (0.17%)

MCK

McKesson

$132.36

-0.34 (-0.26%)

LLY

Eli Lilly

$111.91

-1.4 (-1.24%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

SELB

Selecta Biosciences

$13.80

-1.34 (-8.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 02

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 09

    Nov

  • 27

    Nov

  • 11

    Jan

  • 16

    Feb

  • 18

    Feb

  • 28

    Apr

  • 13

    May

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

, DCPH

Deciphera

$22.22

-4.97 (-18.28%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO 2018 Congress to be…

ABBV

AbbVie

$88.01

-1.93 (-2.15%)

DCPH

Deciphera

$22.22

-4.97 (-18.28%)

TSRO

Tesaro

$41.81

-1.19 (-2.77%)

IMGN

ImmunoGen

$7.44

-0.355 (-4.56%)

REGN

Regeneron

$389.94

-5.45 (-1.38%)

CRSP

Crispr Therapeutics

$36.02

-1.18 (-3.17%)

CLVS

Clovis

$26.41

-3.54 (-11.82%)

MRTX

Mirati Therapeutics

$40.04

-1.82 (-4.35%)

LOXO

Loxo Oncology

$160.01

-7.58 (-4.52%)

RHHBY

Roche

$0.00

(0.00%)

NCNA

NuCana

$18.90

1.9 (11.18%)

CRVS

Corvus Pharmaceuticals

$8.01

-0.1 (-1.23%)

NTGN

Neon Therapeutics

$8.88

0.56 (6.73%)

NKTR

Nektar

$48.23

-1.33 (-2.68%)

EXEL

Exelixis

$16.27

-0.25 (-1.51%)

AVEO

Aveo Pharmaceuticals

$2.50

-0.03 (-1.19%)

KURA

Kura Oncology

$14.38

-1.18 (-7.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 22

    Oct

  • 24

    Oct

  • 28

    Oct

  • 30

    Oct

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 07

    Nov

  • 10

    Nov

  • 26

    Nov

  • 27

    Nov

  • 24

    Dec

  • 14

    Jan

  • 28

    Apr

  • 13

    May

A

Agilent

$64.47

-1.28 (-1.95%)

, AGLE

Aeglea BioTherapeutics

$9.32

-0.58 (-5.86%)

04:55
10/20/18
10/20
04:55
10/20/18
04:55
Conference/Events
American Society of Human Genetics to hold a conference »

ASHG Conference 2018 will…

A

Agilent

$64.47

-1.28 (-1.95%)

AGLE

Aeglea BioTherapeutics

$9.32

-0.58 (-5.86%)

ALXN

Alexion

$125.96

-0.63 (-0.50%)

RHHBY

Roche

$0.00

(0.00%)

BMRN

BioMarin

$103.31

-0.52 (-0.50%)

BIO

Bio-Rad

$280.96

-3.23 (-1.14%)

MSFT

Microsoft

$108.55

0.01 (0.01%)

ILMN

Illumina

$313.31

-7.98 (-2.48%)

FLDM

Fluidigm

$7.49

-0.45 (-5.67%)

HZNP

Horizon Pharma

$19.07

-0.01 (-0.05%)

NVTA

Invitae

$12.86

-0.23 (-1.76%)

NSTG

NanoString

$15.18

-0.41 (-2.63%)

QGEN

Qiagen

$35.91

0.455 (1.28%)

DGX

Quest Diagnostics

$102.49

0.12 (0.12%)

RTRX

Retrophin

$25.34

0.24 (0.96%)

TMO

Thermo Fisher

$227.13

-2.51 (-1.09%)

WTKWY

Wolters Kluwer

$0.00

(0.00%)

ARQL

ArQule

$4.33

-0.38 (-8.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 21

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 30

    Oct

  • 31

    Oct

  • 01

    Nov

  • 01

    Nov

  • 01

    Nov

  • 07

    Nov

  • 07

    Nov

  • 08

    Nov

  • 13

    Nov

  • 27

    Nov

  • 28

    Nov

  • 24

    Dec

  • 18

    Feb

  • 03

    Mar

CLBR

Caliburn International

$0.00

(0.00%)

18:27
10/19/18
10/19
18:27
10/19/18
18:27
Syndicate
Caliburn International files registration statement for proposed IPO »

Caliburn International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

18:10
10/19/18
10/19
18:10
10/19/18
18:10
General news
Saudi Arabia says Kashoggi killed after fight broke out in consulate, CNBC says 

Reference Link

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$276.21

-0.12 (-0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$99.62

2.61 (2.69%)

18:02
10/19/18
10/19
18:02
10/19/18
18:02
Hot Stocks
Celanese raises prices on MIBK, MIBC by EUR120/MT in Europe »

Celanese announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

REGN

Regeneron

$389.94

-5.45 (-1.38%)

, SNY

Sanofi

$44.57

0.12 (0.27%)

17:57
10/19/18
10/19
17:57
10/19/18
17:57
Hot Stocks
Regeneron, Sanofi: FDA approves asthma indication for Dupixent »

Regeneron Pharmaceuticals…

REGN

Regeneron

$389.94

-5.45 (-1.38%)

SNY

Sanofi

$44.57

0.12 (0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 29

    Oct

  • 06

    Nov

  • 28

    Jan

  • 22

    Mar

  • 28

    Apr

  • 13

    May

XLE

Energy Select Sector SPDR

$71.50

-0.67 (-0.93%)

, XLU

Utilities SPDR

$54.57

0.82 (1.53%)

17:55
10/19/18
10/19
17:55
10/19/18
17:55
General news
Week ending ETF Scorecard: Staples, Real Estate, Utilities lead rebound »

S&P500 SECTORS: …

XLE

Energy Select Sector SPDR

$71.50

-0.67 (-0.93%)

XLU

Utilities SPDR

$54.57

0.82 (1.53%)

IYR

DJ US Real Estate Index Fund

$77.83

0.63 (0.82%)

XLP

Consumer Staples Sector SPDR

$54.72

1.225 (2.29%)

XLY

Consumer Discretionary Sector SPDR

$106.34

-1.06 (-0.99%)

XLB

S&P Select Materials SPDR

$53.13

-0.36 (-0.67%)

XLF

Financial Select Sector

$26.66

0.08 (0.30%)

XLV

Health Care Select Sector SPDR

$91.48

-0.93 (-1.01%)

XLK

Technology Select Sector SPDR

$70.00

-0.04 (-0.06%)

XLI

Industrial Select Sector SPDR

$73.17

-0.31 (-0.42%)

GLD

SPDR Gold Trust

$116.01

0.11 (0.09%)

SLV

iShares Silver Trust

$13.74

0.05 (0.37%)

USO

United States Oil Fund

$14.72

0.155 (1.06%)

UNG

United States Natural Gas Fund

$26.81

0.19 (0.71%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$84.90

0.04 (0.05%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$112.69

-0.15 (-0.13%)

TLT

iShares 20+ Year Treasury Bond Fund

$113.73

-0.24 (-0.21%)

IEF

iShares 7-10 Year Treasury Bond ETF

$100.12

-0.12 (-0.12%)

SHY

iShares 1-3 Year Treasury Bond

$82.95

-0.035 (-0.04%)

IWD

iShares Russell 1000 Value

$122.17

0.08 (0.07%)

IWF

iShares Russell 1000 Growth

$145.19

-0.5 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSW

International Seaways

$21.51

0.41 (1.94%)

17:53
10/19/18
10/19
17:53
10/19/18
17:53
Syndicate
Breaking Syndicate news story on International Seaways »

International Seaways…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNR

Monmouth Real Estate

$15.49

0.08 (0.52%)

17:48
10/19/18
10/19
17:48
10/19/18
17:48
Hot Stocks
Monmouth Real Estate acquires industrial building in New Jersey for $85.25M »

Monmouth Real Estate…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.